Beckman wins FDA nod for advanced test used in MI diagnosis

06/20/2013 | RTT News

The FDA has cleared Beckman Coulter, a unit of Danaher, to market its Access AccuTnI+3 troponin I test. The assay, which will run on the company's Access 2 immunoassay platform, has been shown in a clinical study to deliver precise as well as clinically sensitive and specific measurements to help doctors diagnose myocardial infarction.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ